Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLN-499 plus venetoclax in relapsed/refractory solid tumors
jRCT2031260455Phase 1Recruiting
- Sponsor
- Treeline Biosciences
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of TLN-499 and venetoclax in small cell lung cancer (SCLC), apudoma (NET), pleural mesothelioma and 1 more, sponsored by Treeline Biosciences. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of adverse events and serious adverse events and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
TLN-499venetoclax
03
Conditions
small cell lung cancer (SCLC)apudoma (NET)pleural mesotheliomasynovial sarcoma (SS)
Beyond the preview
Go deeper on jRCT2031260455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260455.